相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
MEDI0639: A Novel Therapeutic Antibody Targeting Dll4 Modulates Endothelial Cell Function and Angiogenesis In Vivo
David W. Jenkins et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay for quantitation of the total and unbound RO4929097, a γ-secretase inhibitor targeting Notch signaling, in human plasma
Jianmei Wu et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2011)
Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation
Kevin Vo et al.
MOLECULAR CANCER (2011)
Emergent toxicities associated with the use of mTOR inhibitors in patients with advanced renal carcinoma
Jesus Rodriguez-Pascual et al.
ANTI-CANCER DRUGS (2010)
Therapeutic antibody targeting of individual Notch receptors
Yan Wu et al.
NATURE (2010)
Preclinical Profile of a Potent γ-Secretase Inhibitor Targeting Notch Signaling with In vivo Efficacy and Pharmacodynamic Properties
Leopoldo Luistro et al.
CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Rational targeting of Notch signaling in cancer
P. Rizzo et al.
ONCOGENE (2008)
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia
Teresa Palomero et al.
NATURE MEDICINE (2007)
High-level JAG1 mRNA and protein predict poor outcome in breast cancer
Brendan C. Dickson et al.
MODERN PATHOLOGY (2007)
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus
I. Duran et al.
EUROPEAN JOURNAL OF CANCER (2006)
High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival
M Reedijk et al.
CANCER RESEARCH (2005)
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer
E Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
分享论文
